AR114974A1 - PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS INCLUDING A PYRIDINYL OR SUBSTITUTED PHENYL RESTRAINT, INCLUDING METHODS FOR THEIR USE - Google Patents

PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS INCLUDING A PYRIDINYL OR SUBSTITUTED PHENYL RESTRAINT, INCLUDING METHODS FOR THEIR USE

Info

Publication number
AR114974A1
AR114974A1 ARP190101721A ARP190101721A AR114974A1 AR 114974 A1 AR114974 A1 AR 114974A1 AR P190101721 A ARP190101721 A AR P190101721A AR P190101721 A ARP190101721 A AR P190101721A AR 114974 A1 AR114974 A1 AR 114974A1
Authority
AR
Argentina
Prior art keywords
processes
pyridinyl
restraint
substituted phenyl
tricyclic compounds
Prior art date
Application number
ARP190101721A
Other languages
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR114974A1 publication Critical patent/AR114974A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan en la presente procesos y síntesis de 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2H-irido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y métodos de uso en el tratamiento del cáncer.Provided herein are processes and syntheses of 3 - ((1R, 3R) -1- (2,6-difluoro-4 - ((1- (3-fluoropropyl) azetidin-3-yl) amino) phenyl) -3 -methyl-1,3,4,9-tetrahydro-2H-irido [3,4-b] indol-2-yl) -2,2-difluoropropan-1-ol and methods of use in the treatment of cancer.

ARP190101721A 2018-06-21 2019-06-21 PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS INCLUDING A PYRIDINYL OR SUBSTITUTED PHENYL RESTRAINT, INCLUDING METHODS FOR THEIR USE AR114974A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862687930P 2018-06-21 2018-06-21

Publications (1)

Publication Number Publication Date
AR114974A1 true AR114974A1 (en) 2020-11-11

Family

ID=73543352

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101721A AR114974A1 (en) 2018-06-21 2019-06-21 PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS INCLUDING A PYRIDINYL OR SUBSTITUTED PHENYL RESTRAINT, INCLUDING METHODS FOR THEIR USE

Country Status (2)

Country Link
AR (1) AR114974A1 (en)
MA (1) MA52973B1 (en)

Also Published As

Publication number Publication date
MA52973A (en) 2021-04-28
MA52973B1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
CO2020014604A2 (en) Solid forms of 3 - ((1r, 3r) -1- (2,6-difluoro-4 - ((1- (3-fluoropropyl) azetidin-3- yl) amino) phenyl) -3-methyl-1,3 , 4,9-tetrahydro-2h-pyrido [3,4-b] indol-2-yl) -2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods for use
CL2018003316A1 (en) Compounds for the inhibition of k-ras and for the treatment of cancer. (divisional application 201702786)
CL2019001344A1 (en) Pharmaceutical composition for preventing or treating brain cancer including the crystalline polymorph of tetraarsenic hexoxide and the method for preparing the same.
MX2020001302A (en) Processes for preparing pyrrolidine compounds.
UA122346C2 (en) TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
ECSP20046463A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING DISEASES INVOLVING TISSUES WITH ACIDIC OR HYPOXIC DISEASES
CL2009001212A1 (en) Compounds derived from pyrrolo [2,3-d] pyrimidine, kinase inhibitors; pharmaceutical composition comprising them; and its use in the treatment of vascular dementia, CNS disorder, cancer, among others.
DOP2017000035A (en) INHIBITORS OF PROTEIN KINASE C AND METHODS OF USE
UY29796A1 (en) NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS
GT201600269A (en) DERIVATIVES OF INDANO AND INDOLINA AND THE USE OF THE SAME AS ACTIVATORS OF THE SOLUBLE CYCLING GUANILATE
CL2010001538A1 (en) Compounds derived from substituted pyrazolo-quinazoline, modulators of the activity of protein kinases; pharmaceutical composition; and its use for the treatment of cancer, or a cell proliferative disorder.
CL2022001014A1 (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors. (application divisional 202000791)
ECSP17074645A (en) AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS
CL2008002809A1 (en) Compounds derived from cyanoisoquinoline; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound for the treatment of a drug addiction, in the treatment of a neurodegenerative disorder, such as Alzheimer's, Parkinson's, dementia, among others.
ECSP088366A (en) 1,2-DIARILIMIDAZOLES FOR USE AS CB1 MODULATORS
BR112021019070A2 (en) tyk2 pseudokinase ligands
CL2018001085A1 (en) Indolin-2-one derivatives
ZA200803420B (en) Formulations comprising jorumycin-, reni eramycin-, safracin-related or saframycin-related compounds for treating proliferative diseases
CO2022007814A2 (en) Tyk2 pseudokinase ligands
CL2019002583A1 (en) Dual inhibitors of magl and faah.
ECSP16086196A (en) PHARMACEUTICALLY ACCEPTABLE SALTS OF PIRLINDOLE ENANTIOMERS FOR USE IN MEDICINE
AR114974A1 (en) PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS INCLUDING A PYRIDINYL OR SUBSTITUTED PHENYL RESTRAINT, INCLUDING METHODS FOR THEIR USE
EA201991488A1 (en) POTASSIUM CHANNEL MODULATORS
MX2018008895A (en) 2-oxindole compounds.
MA53485A (en) METHODS FOR PREPARING 4-(8-AMINO-3-[(2S)-1-(BUT-2-YNOYL)-PYRROLIDIN-2-YL]IMIDAZO[1,5-A]-PYRAZIN-1-YL)N -(PYRIDIN-2-YL)-BENZAMIDE